Experience
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
Genzyme Corporation et al.
Novartis Gene Therapies, Inc. et al.
Successfully defended Novartis against Genzyme’s multiple patent infringement actions and inter partes review (IPR) proceedings related to recombinant adeno-associated virus vector technology used in Novartis’ blockbuster, breakthrough gene therapy Zolgensma®. The case settled after four patents were invalidated during claim construction, five patents found not literally infringed, and institution of multiple IPRs.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al., 1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
Related Professionals
- Megan L. Meyers
- Associate
- Atlanta, GA
- +1 404 653 6565
- Shannon M. Patrick
- Associate
- Atlanta, GA
- +1 404 653 6558